Open AccessAtenolol versus Losartan in Children and Young Adults with Marfan's Syndrome
Author(s) -
Ronald V. Lacro,
Harry C. Dietz,
Lynn A. Sleeper,
Anji T. Yetman,
Timothy J. Bradley,
Steven D. Colan,
Gail D. Pearson,
Elif Seda Selamet Tierney,
Jami C. Levine,
Andrew M. Atz,
D. Woodrow Benson,
Alan C. Braverman,
Shan Chen,
Julie De Backer,
Bruce D. Gelb,
Paul Grossfeld,
Gloria L. Klein,
Wyman W. Lai,
Aimée Liou,
Bart Loeys,
Larry W. Markham,
Aaron K. Olson,
Stephen M. Paridon,
Victoria L. Pemberton,
Mary Ella Pierpont,
Reed E. Pyeritz,
Elizabeth Radojewski,
Mary J. Roman,
Angela M. Sharkey,
Mario Stylianou,
Stephanie Burns Wechsler,
Luciana Young,
Lynn Mahony
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1404731
Subject(s) - atenolol , medicine , marfan syndrome , losartan , aortic root , aortic dissection , cardiology , aorta , angiotensin ii , blood pressure
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom